Literature DB >> 3160462

Effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex.

P D Williams, G H Hottendorf.   

Abstract

Purified renal membrane vesicles were utilized to gain indirect information regarding the renal handling of cisplatin. The effects of cisplatin on prototypical organic anion (p-amino-hippurate, PAH) and cation (N1-methylnicotinamide; tetraethylammonium, TEA) transport in brush border and basolateral membrane vesicles prepared from rat kidney cortex were observed. While cisplatin inhibited organic cation transport (N1-methylnicotinamide; TEA) in brush border and basolateral membranes, no interaction with the organic anion (p-amino-hippurate) system was observed. Kinetic analyses revealed that cisplatin is a competitive inhibitor of TEA transport in brush border membranes with a ki of 0.12 mM. While the relationship between organic cation transport inhibition and cisplatin nephrotoxicity is unknown, it may suggest that the cisplatin complex itself is transported into the kidney by the organic cation system. The reported effect of the organic anion, probenecid, on the renal handling of cisplatin is discussed in light of these results.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3160462

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

Review 1.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

2.  Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.

Authors:  K Hanada; K Odaka; A Kudo; H Ogata
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

3.  Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.

Authors:  Ryan M Franke; Ashley M Kosloske; Cynthia S Lancaster; Kelly K Filipski; Chaoxin Hu; Oliver Zolk; Ron H Mathijssen; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2010-07-02       Impact factor: 12.531

4.  Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-diphenylethylenediamine) platinum(II) sulfates and specific platinum accumulation.

Authors:  H Reile; G Bernhardt; M Koch; H Schönenberger; M Hollstein; F Lux
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats.

Authors:  T Hayashi; Y Watanabe; K Kumano; R Kitayama; T Muratani; T Yasuda; I Saikawa; J Katahira; T Kumada; K Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

6.  Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.

Authors:  Jing Li; Seongho Kim; Xianyi Sha; Richard Wiegand; Jianmei Wu; Patricia LoRusso
Journal:  Clin Cancer Res       Date:  2014-06-19       Impact factor: 12.531

7.  Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance.

Authors:  J A Sprowl; L van Doorn; S Hu; L van Gerven; P de Bruijn; L Li; A A Gibson; R H Mathijssen; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2013-07-17       Impact factor: 6.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.